pyrazines has been researched along with dasatinib in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (12.50) | 29.6817 |
| 2010's | 14 (87.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Scheinfeld, N | 1 |
| Birgens, H; Brown, Pde N; Dalseg, AM; Dufva, IH; Hasselbalch, HC; Jensen, MK; Vangsted, A | 1 |
| Allan, EK; Bhatia, R; Chu, S; Crawford, L; Heaney, NB; Holyoake, TL; Irvine, AE; Jorgensen, HG; Kazmi, SM; Pellicano, F; Zhang, B | 1 |
| Gong, Y; Liu, T; Meng, W; Xing, H | 1 |
| Colado, E; de Queiroz Crusoe, E; Delgado, M; Fernandez-Lazaro, D; Garayoa, M; Garcia-Gomez, A; Gutierrez, NC; Lee, FY; Maiso, P; Martin-Sanchez, J; Ocio, EM; San-Segundo, L | 1 |
| Arshad Siddiqui, M; Belanger, DB; Bracken, JB; Curran, PJ; Malkowski, M; Miao, H; Shipps, GW; Wang, Y; Zeng, H | 1 |
| Andriamanana, I; Duretz, B; Gana, I; Hulin, A | 1 |
| Chen, SS; Falchook, G; Fok, JY; Fu, S; Heymach, J; Hong, D; Janku, F; Kurzrock, R; Naing, A; Piha-Paul, S; Stephen, B; Tsimberidou, AM; Wheler, J | 1 |
| Bertomeu, T; Bucur, O; Dewar, R; Goganau, I; Khosravi-Far, R; Pennarun, B; Petrescu, SM; Stancu, AL | 1 |
| Chen, S; Chen, W; Dong, Y; He, X; Liang, C; Ma, J; Zhang, B; Zhang, X | 1 |
| Jung, YS; Kim, DW; Kim, M; Lee, JH; Park, HJ | 1 |
| Bonetti, B; Cavenee, WK; Chopra, R; Cloughesy, TF; Ding, X; Gini, B; Gu, Y; Heath, JR; Herrmann, K; Hwang, K; Ikegami, S; James, CD; Johnson, D; Kim, J; Li, X; Masui, K; Matsutani, T; Mischel, PS; Shin, YS; Su, Y; Wei, W; Xue, M; Yang, H; Zhou, J | 1 |
| Abbenante, MC; Derenzini, E; Ferrari, A; Ghelli Luserna Di Rorà, A; Guadagnuolo, V; Iacobucci, I; Imbrogno, E; Martinelli, G; Paolini, S; Papayannidis, C; Parisi, S; Robustelli, V; Sartor, C | 1 |
| Baek, JH; Choi, Y; Heo, SK; Jeong, YK; Jo, JC; Kim, H; Kim, JY; Koh, S; Min, YJ; Noh, EK | 1 |
| Baek, B; Hyun, SY; Kim, B; Kim, Y; Lee, HJ; Lee, HY; Lee, J; Min, HY; Pham, PC | 1 |
| Hu, Y; Jiang, HW; Li, CG; Mei, H; Peng, YZ; Tang, L; Xu, M; Zhang, H | 1 |
2 review(s) available for pyrazines and dasatinib
| Article | Year |
|---|---|
A review of deferasirox, bortezomib, dasatinib, and cyclosporine eye drops: possible uses and known side effects in cutaneous medicine.
Topics: Animals; Antineoplastic Agents; Benzoates; Boronic Acids; Bortezomib; Cyclosporine; Dasatinib; Deferasirox; Humans; Iron Chelating Agents; Ophthalmic Solutions; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Randomized Controlled Trials as Topic; Skin Diseases; Skin Neoplasms; Thiazoles; Triazoles | 2007 |
[Novel medical treatment modalities in hematology].
Topics: Aminoglycosides; Anemia, Hemolytic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Benzoates; Boronic Acids; Bortezomib; Carbazoles; Carrier Proteins; Cyclophosphamide; Dasatinib; Furans; Gemtuzumab; Hematologic Diseases; Humans; Hydrazines; Imatinib Mesylate; Immunologic Factors; Indoles; Lenalidomide; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Multiple Myeloma; Myelodysplastic Syndromes; Piperazines; Purpura, Thrombocytopenic; Pyrazines; Pyrazoles; Pyrimidines; Receptors, Fc; Recombinant Fusion Proteins; Rituximab; Thalidomide; Thiazoles; Thrombopoietin; Vidarabine | 2008 |
1 trial(s) available for pyrazines and dasatinib
| Article | Year |
|---|---|
Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cetuximab; Dasatinib; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Quinazolines; Retrospective Studies; Sirolimus; Survival; Thiazoles; Treatment Outcome | 2013 |
13 other study(ies) available for pyrazines and dasatinib
| Article | Year |
|---|---|
Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells.
Topics: Animals; Antigens, CD34; Apoptosis; Boronic Acids; Bortezomib; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Dasatinib; Drug Synergism; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, SCID; Mutant Proteins; Proteasome Inhibitors; Pyrazines; Pyrimidines; Thiazoles; Time Factors; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2010 |
An investigation of reversal of imatinib resistance in the Bcr-Abl positive imatinib-resistant cell line K562r by dasatinib, nilotinib, rapamycin and bortezomib.
Topics: Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Piperazines; Pyrazines; Pyrimidines; Signal Transduction; Sirolimus; Thiazoles; TOR Serine-Threonine Kinases; Up-Regulation | 2011 |
Transcriptomic rationale for the synergy observed with dasatinib + bortezomib + dexamethasone in multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Cells, Cultured; Dasatinib; Dexamethasone; Drug Synergism; Gene Expression Profiling; Humans; Multiple Myeloma; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Thiazoles; Transcriptome | 2012 |
Discovery of novel imidazo[1,2-a]pyrazin-8-amines as Brk/PTK6 inhibitors.
Topics: Adaptor Proteins, Signal Transducing; Animals; Aurora Kinases; Breast Neoplasms; Computer Simulation; Dasatinib; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Design; Drug Discovery; Drug Screening Assays, Antitumor; Female; Humans; Imidazoles; Inhibitory Concentration 50; Melanocytes; Mice; Molecular Targeted Therapy; Neoplasm Proteins; Oncogenes; Phenotype; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogenes; Pyrazines; Pyrimidines; RNA-Binding Proteins; Structure-Activity Relationship; Thiazoles | 2011 |
Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS.
Topics: Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Chromatography, Liquid; Dasatinib; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Lapatinib; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Pyrazines; Pyrimidines; Pyrroles; Quinazolines; Reproducibility of Results; Sorafenib; Sunitinib; Tandem Mass Spectrometry; Thiazoles | 2013 |
Combination of bortezomib and mitotic inhibitors down-modulate Bcr-Abl and efficiently eliminates tyrosine-kinase inhibitor sensitive and resistant Bcr-Abl-positive leukemic cells.
Topics: Benzamides; Boronic Acids; Bortezomib; Caspases; Cell Death; Cell Line, Tumor; Dasatinib; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Fusion Proteins, bcr-abl; Heterocyclic Compounds, 2-Ring; Humans; Imatinib Mesylate; JNK Mitogen-Activated Protein Kinases; Leukemia; Mitosis; Models, Biological; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pteridines; Pyrazines; Pyrimidines; Signal Transduction; STAT5 Transcription Factor; Thiazoles | 2013 |
Bortezomib enhances the therapeutic efficacy of dasatinib by promoting c-KIT internalization-induced apoptosis in gastrointestinal stromal tumor cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptotic Protease-Activating Factor 1; Biomarkers, Tumor; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle; Cell Proliferation; Dasatinib; Drug Synergism; Fluorescent Antibody Technique; Gastrointestinal Stromal Tumors; HSP90 Heat-Shock Proteins; Humans; Immunoprecipitation; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; Thiazoles; Tumor Cells, Cultured | 2015 |
Acneiform eruptions caused by various second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia.
Topics: Acneiform Eruptions; Adult; Benzamides; Dasatinib; Facial Dermatoses; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Pyrimidines; Young Adult | 2016 |
Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma.
Topics: Adaptation, Physiological; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Butadienes; Dasatinib; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gene Expression Profiling; Genes, erbB-1; Glioblastoma; Humans; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice; Models, Biological; Molecular Targeted Therapy; Multiprotein Complexes; Mutation; Neoplasm Proteins; Nitriles; Phosphoproteins; Protein Kinase Inhibitors; Proteomics; Pyrazines; Selection, Genetic; Signal Transduction; Single-Cell Analysis; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2016 |
Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia.
Topics: Adenine Nucleotides; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Cell Cycle; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Checkpoint Kinase 2; Clofarabine; Dasatinib; Drug Synergism; Humans; Imatinib Mesylate; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrazines; Pyrazoles | 2016 |
Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death.
Topics: Animals; Apoptosis; Apoptotic Protease-Activating Factor 1; Benzamides; Cell Line, Tumor; Dasatinib; Drug Delivery Systems; Female; Gene Expression Regulation, Leukemic; HSP90 Heat-Shock Proteins; Humans; Leukemia, Myeloid, Acute; Male; Mice; Mice, Nude; Proto-Oncogene Proteins c-kit; Pyrazines; Xenograft Model Antitumor Assays | 2017 |
Development of a 4-aminopyrazolo[3,4-d]pyrimidine-based dual IGF1R/Src inhibitor as a novel anticancer agent with minimal toxicity.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dasatinib; Humans; Imidazoles; Immunohistochemistry; MCF-7 Cells; Pyrazines; Pyrimidines; Receptor, IGF Type 1; Receptors, Somatomedin; src-Family Kinases; Xenograft Model Antitumor Assays | 2018 |
Comparative efficacy and tolerability of front-line treatments for newly diagnosed chronic-phase chronic myeloid leukemia: an update network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Dose-Response Relationship, Drug; Female; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Male; Network Meta-Analysis; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Survival Analysis; Treatment Outcome | 2019 |